Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Retained Earnings: 2017-2024

Historic Retained Earnings for Dianthus Therapeutics (DNTH) over the last 6 years, with Dec 2024 value amounting to -$174.4 million.

  • Dianthus Therapeutics' Retained Earnings fell 86.51% to -$272.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$272.3 million, marking a year-over-year decrease of 86.51%. This contributed to the annual value of -$174.4 million for FY2024, which is 95.02% down from last year.
  • According to the latest figures from FY2024, Dianthus Therapeutics' Retained Earnings is -$174.4 million, which was down 95.02% from -$89.4 million recorded in FY2023.
  • Dianthus Therapeutics' Retained Earnings' 5-year high stood at -$45.9 million during FY2022, with a 5-year trough of -$174.4 million in FY2024.
  • In the last 3 years, Dianthus Therapeutics' Retained Earnings had a median value of -$89.4 million in 2023 and averaged -$103.2 million.
  • Data for Dianthus Therapeutics' Retained Earnings shows a maximum YoY tumbled of 95.02% (in 2024) over the last 5 years.
  • Yearly analysis of 3 years shows Dianthus Therapeutics' Retained Earnings stood at -$45.9 million in 2022, then tumbled by 94.96% to -$89.4 million in 2023, then tumbled by 95.02% to -$174.4 million in 2024.